AUSTIN, TX ― April 2, 2019 ― Savara
Inc.
(NASDAQ:SVRA), an orphan lung disease company, today announced that Rob
Neville, Chief Executive Officer, will present at the H.C. Wainwright Global
Life Sciences conference on Tuesday, April 9, 2019 at 1:50 PM GMT / 8:50 AM
EST. The conference will be held at the JW Marriott Grosvenor House London.
Interested parties can access a live audio
webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to
the company's website at least 15 minutes prior to the start of the
presentation to ensure sufficient time for any software download that may be
required for the webcast. An archived presentation will be available on Savara's
website for 30 days.
About Savara
Savara is an orphan lung disease company. Savara's pipeline
comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar
proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial
(NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected
individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage
inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung
infection in CF. Savara's strategy involves expanding its pipeline of
potentially best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of becoming a
leading company in its field. The most recent acquisition is aerosolized
amikacin/fosfomycin, a Phase 2-ready, proprietary combination antibiotic, which
has demonstrated potent and broad-spectrum antibacterial activity against
highly drug resistant pathogens. Savara's management team has significant
experience in orphan drug development and pulmonary medicine, identifying unmet
needs, developing and acquiring new
product candidates, and effectively advancing them to approvals and
commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)
Contacts:
Savara Inc. IR/PR:
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366
For IR: Solebury Trout
Gitanjali
Jain Ogawa (Gogawa@troutgroup.com)
(646) 378-2949